Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diroximel fumarate in relapsing multiple sclerosis in Asia-Pacific
NCT05083923Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of diroximel fumarate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoints: Treatment Emergent Adverse Events at 24 weeks, Potentially Clinically Significant Abnormalities in Laboratory Parameters at 24 weeks and 3 more. Started Nov 2021; status: completed.
02
Drugs
diroximel fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05083923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083923.